Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of AZD9291 in EGFRm+ NSCLC
NCT02163733Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve from 0 to 72 hours and Maximum Plasma Concentration at Day 10. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02163733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163733.